165 related articles for article (PubMed ID: 34575646)
1. Neuroblastoma and DIPG Organoid Coculture System for Personalized Assessment of Novel Anticancer Immunotherapies.
M Kholosy W; Derieppe M; van den Ham F; Ober K; Su Y; Custers L; Schild L; M J van Zogchel L; M Wellens L; R Ariese H; Szanto CL; Wienke J; Dierselhuis MP; van Vuurden D; Dolman EM; Molenaar JJ
J Pers Med; 2021 Aug; 11(9):. PubMed ID: 34575646
[TBL] [Abstract][Full Text] [Related]
2. The immune landscape of neuroblastoma: Challenges and opportunities for novel therapeutic strategies in pediatric oncology.
Wienke J; Dierselhuis MP; Tytgat GAM; Künkele A; Nierkens S; Molenaar JJ
Eur J Cancer; 2021 Feb; 144():123-150. PubMed ID: 33341446
[TBL] [Abstract][Full Text] [Related]
3. Tumour organoids and assembloids: Patient-derived cancer avatars for immunotherapy.
Mei J; Liu X; Tian HX; Chen Y; Cao Y; Zeng J; Liu YC; Chen Y; Gao Y; Yin JY; Wang PY
Clin Transl Med; 2024 Apr; 14(4):e1656. PubMed ID: 38664597
[TBL] [Abstract][Full Text] [Related]
4. Implementation of immunotherapy into the treatment of neuroblastoma - single center experience with the administration of dinutuximab and management of its adverse effects.
Achbergerová M; Hederová S; Mikesková M; Husáková K; Hrašková A; Kolenová A
Klin Onkol; 2020; 33(5):372-378. PubMed ID: 33108882
[TBL] [Abstract][Full Text] [Related]
5. Neuroblastoma: an ongoing cold front for cancer immunotherapy.
Kennedy PT; Zannoupa D; Son MH; Dahal LN; Woolley JF
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37993280
[TBL] [Abstract][Full Text] [Related]
6. MRI-guided focused ultrasound enhances drug delivery in experimental diffuse intrinsic pontine glioma.
Ishida J; Alli S; Bondoc A; Golbourn B; Sabha N; Mikloska K; Krumholtz S; Srikanthan D; Fujita N; Luck A; Maslink C; Smith C; Hynynen K; Rutka J
J Control Release; 2021 Feb; 330():1034-1045. PubMed ID: 33188825
[TBL] [Abstract][Full Text] [Related]
7. Activated Natural Killer Cells in Combination with Anti-GD2 Antibody Dinutuximab Improve Survival of Mice after Surgical Resection of Primary Neuroblastoma.
Barry WE; Jackson JR; Asuelime GE; Wu HW; Sun J; Wan Z; Malvar J; Sheard MA; Wang L; Seeger RC; Kim ES
Clin Cancer Res; 2019 Jan; 25(1):325-333. PubMed ID: 30232225
[TBL] [Abstract][Full Text] [Related]
8. Preclinical evaluation of convection-enhanced delivery of liposomal doxorubicin to treat pediatric diffuse intrinsic pontine glioma and thalamic high-grade glioma.
Sewing ACP; Lagerweij T; van Vuurden DG; Meel MH; Veringa SJE; Carcaboso AM; Gaillard PJ; Peter Vandertop W; Wesseling P; Noske D; Kaspers GJL; Hulleman E
J Neurosurg Pediatr; 2017 May; 19(5):518-530. PubMed ID: 28291423
[TBL] [Abstract][Full Text] [Related]
9. Organoids to study immune functions, immunological diseases and immunotherapy.
Ye W; Luo C; Li C; Huang J; Liu F
Cancer Lett; 2020 May; 477():31-40. PubMed ID: 32112908
[TBL] [Abstract][Full Text] [Related]
10. Managing Adverse Events Associated with Dinutuximab Beta Treatment in Patients with High-Risk Neuroblastoma: Practical Guidance.
Barone G; Barry A; Bautista F; Brichard B; Defachelles AS; Herd F; Manzitti C; Reinhardt D; Rubio PM; Wieczorek A; van Noesel MM
Paediatr Drugs; 2021 Nov; 23(6):537-548. PubMed ID: 34541620
[TBL] [Abstract][Full Text] [Related]
11. Diffuse Intrinsic Pontine Glioma : Clinical Features, Molecular Genetics, and Novel Targeted Therapeutics.
Mathew RK; Rutka JT
J Korean Neurosurg Soc; 2018 May; 61(3):343-351. PubMed ID: 29742880
[TBL] [Abstract][Full Text] [Related]
12. TGFβR1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells.
Tran HC; Wan Z; Sheard MA; Sun J; Jackson JR; Malvar J; Xu Y; Wang L; Sposto R; Kim ES; Asgharzadeh S; Seeger RC
Clin Cancer Res; 2017 Feb; 23(3):804-813. PubMed ID: 27756784
[TBL] [Abstract][Full Text] [Related]
13. Dual targeting of mitochondrial function and mTOR pathway as a therapeutic strategy for diffuse intrinsic pontine glioma.
Tsoli M; Liu J; Franshaw L; Shen H; Cheng C; Jung M; Joshi S; Ehteda A; Khan A; Montero-Carcabosso A; Dilda PJ; Hogg P; Ziegler DS
Oncotarget; 2018 Jan; 9(7):7541-7556. PubMed ID: 29484131
[TBL] [Abstract][Full Text] [Related]
14. Development of a clinical scale for assessment of patients with diffuse intrinsic pontine glioma (DIPG) receiving experimental therapy: the PONScore.
Hollingworth MA; Zacharoulis S
J Neurooncol; 2020 Sep; 149(2):263-272. PubMed ID: 32902768
[TBL] [Abstract][Full Text] [Related]
15. Model of Patient-Specific Immune-Enhanced Organoids for Immunotherapy Screening: Feasibility Study.
Votanopoulos KI; Forsythe S; Sivakumar H; Mazzocchi A; Aleman J; Miller L; Levine E; Triozzi P; Skardal A
Ann Surg Oncol; 2020 Jun; 27(6):1956-1967. PubMed ID: 31858299
[TBL] [Abstract][Full Text] [Related]
16. Anti-GD2-IRDye800CW as a targeted probe for fluorescence-guided surgery in neuroblastoma.
Wellens LM; Deken MM; Sier CFM; Johnson HR; de la Jara Ortiz F; Bhairosingh SS; Houvast RD; Kholosy WM; Baart VM; Pieters AMMJ; de Krijger RR; Molenaar JJ; Wehrens EJ; Dekkers JF; Wijnen MHWA; Vahrmeijer AL; Rios AC
Sci Rep; 2020 Oct; 10(1):17667. PubMed ID: 33077751
[TBL] [Abstract][Full Text] [Related]
17. Dinutuximab: An Anti-GD2 Monoclonal Antibody for High-Risk Neuroblastoma.
Ploessl C; Pan A; Maples KT; Lowe DK
Ann Pharmacother; 2016 May; 50(5):416-22. PubMed ID: 26917818
[TBL] [Abstract][Full Text] [Related]
18. Initiation of immunotherapy with activated natural killer cells and anti-GD2 antibody dinutuximab prior to resection of primary neuroblastoma prolongs survival in mice.
Zobel MJ; Zamora AK; Wu HW; Sun J; Lascano D; Malvar J; Wang L; Sheard MA; Seeger RC; Kim ES
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33428582
[TBL] [Abstract][Full Text] [Related]
19. Organoid technology and applications in cancer research.
Xu H; Lyu X; Yi M; Zhao W; Song Y; Wu K
J Hematol Oncol; 2018 Sep; 11(1):116. PubMed ID: 30219074
[TBL] [Abstract][Full Text] [Related]
20. Development of the SIOPE DIPG network, registry and imaging repository: a collaborative effort to optimize research into a rare and lethal disease.
Veldhuijzen van Zanten SEM; Baugh J; Chaney B; De Jongh D; Sanchez Aliaga E; Barkhof F; Noltes J; De Wolf R; Van Dijk J; Cannarozzo A; Damen-Korbijn CM; Lieverst JA; Colditz N; Hoffmann M; Warmuth-Metz M; Bison B; Jones DTW; Sturm D; Gielen GH; Jones C; Hulleman E; Calmon R; Castel D; Varlet P; Giraud G; Slavc I; Van Gool S; Jacobs S; Jadrijevic-Cvrlje F; Sumerauer D; Nysom K; Pentikainen V; Kivivuori SM; Leblond P; Entz-Werle N; von Bueren AO; Kattamis A; Hargrave DR; Hauser P; Garami M; Thorarinsdottir HK; Pears J; Gandola L; Rutkauskiene G; Janssens GO; Torsvik IK; Perek-Polnik M; Gil-da-Costa MJ; Zheludkova O; Shats L; Deak L; Kitanovski L; Cruz O; Morales La Madrid A; Holm S; Gerber N; Kebudi R; Grundy R; Lopez-Aguilar E; Zapata-Tarres M; Emmerik J; Hayden T; Bailey S; Biassoni V; Massimino M; Grill J; Vandertop WP; Kaspers GJL; Fouladi M; Kramm CM; van Vuurden DG;
J Neurooncol; 2017 Apr; 132(2):255-266. PubMed ID: 28110411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
